Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03277638 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

StatusCompleted
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary completion date changed from estimate of Dec 2026 to Apr 15, 2026
    • Eligibility criteria expanded, about 73 words
    • Study description expanded, about 11 words
  2. Primary and study completion pushed from Jun 2026 to Dec 2026v25
  3. Re-verified, no change to tracked fieldsv24
  4. Primary completion pushed from Mar 2026 to Jun 2026v23
  5. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 34 to confirmed 32
    • Primary completion date: Dec 2025 to Mar 2026
    • Site details revised
    v22
Show 20 earlier versionsHide 20 earlier versions
  1. Primary completion date: Jun 15, 2025 to Dec 2025
    • Study completion date: Dec 15, 2025 to Jun 2026
    v21
  2. Primary completion date: Dec 15, 2024 to Jun 15, 2025
    • Study completion date: Jun 15, 2025 to Dec 15, 2025
    v20
  3. Primary completion date: Jun 15, 2024 to Dec 15, 2024
    • Study completion date: Dec 15, 2024 to Jun 15, 2025
    v19
  4. Primary completion date: Dec 15, 2023 to Jun 15, 2024v18
  5. Trial status: Suspended to Recruiting
    • Site details revised
    v17
  6. Primary completion date: Jun 15, 2023 to Dec 15, 2023
    • Sponsor's reason: Administrative hold: Contracting issue to Administrative Hold: Contracting Issues
    • Study completion date: Jun 15, 2024 to Dec 15, 2024
    v16
  7. Trial status: Recruiting to Suspended Sponsor's reason: Administrative hold: Contracting issue
    • Site details revised
    v15
  8. Trial status: Suspended to Recruiting
    • Site details revised
    v14
  9. Trial status: Active, Not Recruiting to Suspended Sponsor's reason: Principal Investigator change pending
    • Primary completion date: Dec 2022 to Jun 15, 2023
    • Study completion date: Dec 2023 to Jun 15, 2024
    v13
  10. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v12
  11. Eligibility criteria expanded, about 36 wordsv11
  12. Primary completion date: Dec 2021 to Dec 2022
    • Study completion date: Dec 2021 to Dec 2023
    v10
  13. Primary and study completion dates: Apr 2021 to Dec 2021v9
  14. Primary endpoints revised (2)v8 Show 4 more changesShow less
    • Primary completion date: Dec 2020 to Apr 2021
    • Study completion date: Jan 2021 to Apr 2021
    • Secondary endpoints revised (5)
    • Study site revised
  15. Re-verified, no change to tracked fieldsv7
  16. Primary completion date: May 2020 to Dec 2020
    • Study completion date: Jul 2020 to Jan 2021
    v6
  17. Primary completion date: Dec 2019 to May 2020
    • Study completion date: Feb 2020 to Jul 2020
    v5
  18. Primary completion date: Feb 2019 to Dec 2019v4
  19. Study title expanded, about 2 wordsv3
  20. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Oct 2017 to Nov 29, 2017
    • Eligibility criteria revised
    • Site details revised
    • Study description expanded, about 2 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors. Pembrolizumab is an investigational (experimental) drug that works by helping participants' immune system work correctly to detect and fight cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA), for this use, though it is approved to treat other cancers.
Trial Details
NCT Number NCT03277638
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 Glioblastoma, Adult
Related terms Brain Neoplasms, Glioblastoma
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov